 Shares of Mersana Therapeutics NASDAQ:MRSN remained unaffected after the company reported Q2 results.Quarterly Results Earnings per share were up 8.33 year over year to 0.33, which missed the estimate of 0.30.Revenue of 796,000 rose by 294.06 year over year, which beat the estimate of 300,000.Looking Ahead Earnings guidance hasnt been issued by the company for now.Revenue guidance hasnt been issued by the company for now.Details Of The Call Date: Aug 07, 2020View more earnings on MRSNTime: 08:00 AMET Webcast URL: Action 52-week high: 24.9752-week low: 1.32Price action over last quarter: Up 110.81Company Overview Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersanas product candidate, XMT-1536, is in Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersanas platform to advance their ADC pipelines.See more from Benzinga Earnings Scheduled For August 7, 2020 Earnings Preview for Mersana Therapeutics Stocks That Hit 52-Week Highs On WednesdayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 